Amia Capital LLP Crispr Therapeutics Ag Transaction History

Amia Capital LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$79.67 - $173.23 $348,476 - $757,708	-4,374 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$78.5 - $100.64 $21,352 - $27,374	272 Added 6.63%	4,374 $366,000
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $87,125 - $172,101	-2,263 Reduced 35.55%	4,102 $301,000
Q1 2020 May 15, 2020	SELL	$33.68 - $62.53 $69,448 - $128,936	-2,062 Reduced 24.47%	6,365 $270,000
Q4 2019 Feb 13, 2020	BUY	$36.68 - $73.13 $309,102 - $616,266	8,427 New	8,427 $513,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.19B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Amia Capital LLP, based on Form 13F filings with the SEC.

Stay updated on Amia Capital LLP with notifications on news.